Literature DB >> 21429990

Fracture risk assessed by Fracture Risk Assessment Tool (FRAX) compared with fracture risk derived from population fracture rates.

Katrine Hass Rubin1, Bo Abrahamsen, Anne Pernille Hermann, Mickael Bech, Jeppe Gram, Kim Brixen.   

Abstract

PURPOSE: To evaluate the performance of the Swedish version of Fracture Risk Assessment Tool (FRAX)) without bone mass density (BMD) in a Danish population to examine the possibility of applying this version to Danish women.
METHODS: From the Danish National Register of social security numbers, we randomly selected 5000 women living in the region of Southern Denmark aged 40-90 years to receive a mailed questionnaire concerning risk factors for osteoporosis based on FRAX. The predicted 10-year probability of hip fractures was calculated for each woman returning a complete questionnaire using the Swedish version of FRAX. The observed 10-year hip fracture risk was also calculated for each woman using age-specific hip fracture rates from the National Hospital Discharge Register and National survival tables.
RESULTS: A total of 4194 (84%) women responded to the questionnaire and 3636 (73%) gave complete information and were included in the analysis. Using FRAX, the predicted 10-year fracture risk was 7.6%, ranging from 0.3 to 25.0% at the age of 41-50 and 81-90, respectively, while the corresponding observed fracture risk was 7.6%, ranging from 0.4 to 24.0%, respectively and not significantly different from the predicted risk (p = 0.92).
CONCLUSIONS: The Swedish version of FRAX without BMD is applicable to Danish women.

Entities:  

Mesh:

Year:  2011        PMID: 21429990     DOI: 10.1177/1403494811402412

Source DB:  PubMed          Journal:  Scand J Public Health        ISSN: 1403-4948            Impact factor:   3.021


  5 in total

1.  Self-perceived facture risk: factors underlying women's perception of risk for osteoporotic fractures: the Risk-Stratified Osteoporosis Strategy Evaluation study (ROSE).

Authors:  M J Rothmann; J Ammentorp; M Bech; J Gram; O W Rasmussen; R Barkmann; C C Glüer; A P Hermann
Journal:  Osteoporos Int       Date:  2014-11-01       Impact factor: 4.507

2.  Non-participation in systematic screening for osteoporosis-the ROSE trial.

Authors:  M J Rothmann; S Möller; T Holmberg; M Højberg; J Gram; M Bech; K Brixen; A P Hermann; C-C Glüer; R Barkmann; K H Rubin
Journal:  Osteoporos Int       Date:  2017-09-05       Impact factor: 4.507

Review 3.  Comparison between various fracture risk assessment tools.

Authors:  W D Leslie; L M Lix
Journal:  Osteoporos Int       Date:  2014-01       Impact factor: 4.507

4.  Use of antiosteoporotic medication in the Danish ROSE population-based screening study.

Authors:  M P Høiberg; K H Rubin; T Holmberg; M J Rothmann; S Möller; J Gram; M Bech; K Brixen; A P Hermann
Journal:  Osteoporos Int       Date:  2019-03-26       Impact factor: 4.507

Review 5.  A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Authors:  John A Kanis; Nicholas C Harvey; Cyrus Cooper; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2016-07-27       Impact factor: 2.617

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.